Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report)'s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $21.13 and last traded at $21.30, with a volume of 24716 shares changing hands. The stock had previously closed at $22.43.
Analyst Ratings Changes
A number of research firms have recently commented on KYTX. Morgan Stanley began coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They set an "overweight" rating and a $40.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an "overweight" rating and a $39.00 price objective on the stock. Leerink Partnrs reiterated an "outperform" rating on shares of Kyverna Therapeutics in a report on Monday, March 4th. Wells Fargo & Company initiated coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They issued an "overweight" rating and a $44.00 price target on the stock. Finally, SVB Leerink assumed coverage on shares of Kyverna Therapeutics in a report on Monday, March 4th. They issued an "outperform" rating and a $48.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $42.75.
Check Out Our Latest Report on KYTX
Kyverna Therapeutics Stock Performance
The company has a 50 day simple moving average of $26.48.
Insider Buying and Selling
In other news, major shareholder Northpond Ventures Iii Gp, Llc purchased 450,000 shares of the company's stock in a transaction that occurred on Monday, February 12th. The stock was purchased at an average cost of $22.00 per share, with a total value of $9,900,000.00. Following the purchase, the insider now owns 450,000 shares in the company, valued at $9,900,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
About Kyverna Therapeutics
(
Get Free Report)
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Read More
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
